Chief Executive of AstraZeneca, Pascal Soriot, said that their COVID-19 vaccine would be effective by the end of this year. They have speeded up the manufacturing process to supply hundreds of millions of doses in January.
The Anglo-Swedish drugmaker and the University of Oxford are working together to manufacture COVID-19 vaccines in late-stage trials in the U.S., Britain, and other countries to determine its safety and effectiveness. Once their results are reported, regulators will have to approve the vaccine for widespread use.
Soriot told media, “We have aligned the timing of delivery of vials to the timing of the clinical trial readout.’’
“On a global basis, we’ll be ready to supply hundreds of millions of doses of vaccine around the world by January.”
Governments and public health authorities are desperately waiting for the data about the developments of a vaccine as they look for a way to fight the COVID-19 pandemic without the restrictions on business and social life punishing the world economy. Infection rates rise in many countries amid a second wave of the virus that has killed more than 1.2 million people worldwide.
AstraZeneca and Oxford have pledged to provide their COVID-19 vaccine on a non-profit basis during the pandemic.